Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company")manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announces today its H2 2025 financial communication calendar.
Publication | Date |
H1 2025 results | October 23, 2025, release after market close |
The Company will participate in upcoming investor events:
European MidCap Event 2025
September 30 October 1st, 2025 Paris, France
Portzamparc Biotech and Healthcare Sector Investor Seminar
October 1-2, 2025 (digital)
Investor Access Conference 2025
October 7-8, 2025 Paris, France
Please get in touch through the respective event booking systems, if you would like to request a meeting with Median management at these events. Events are for institutional investors only.
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908162115/en/
Contacts:
MEDIAN TECHNOLOGIES
Emmanuelle Leygues
VP, Corporate Marketing Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Investors SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com
U.S. media investors COHESION BUREAU
Chris Maggos
+41 79 367 6254
chris.maggos@cohesionbureau.com
Press ULYSSE COMMUNICATION
Bruno Arabian
+33 6 87 88 47 26
barabian@ulysse-communication.com
Nicolas Entz
+33 6 33 67 31 54
nentz@ulysse-communication.com
